Focused On-demand Library for Proliferation-associated protein 2G4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UQ80

UPID:

PA2G4_HUMAN

Alternative names:

Cell cycle protein p38-2G4 homolog; ErbB3-binding protein 1

Alternative UPACC:

Q9UQ80; O43846; Q9UM59

Background:

Proliferation-associated protein 2G4, also known as ErbB3-binding protein 1, plays a crucial role in various cellular processes including growth regulation, apoptosis suppression, and cell differentiation. It functions within the ERBB3-regulated signal transduction pathway and acts as a corepressor of the androgen receptor. This protein is involved in ribosome assembly and mediates cap-independent translation of specific viral IRESs, highlighting its importance in cellular machinery.

Therapeutic significance:

Understanding the role of Proliferation-associated protein 2G4 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as growth regulation and apoptosis makes it a promising target for drug discovery efforts aimed at treating diseases where these processes are dysregulated.